Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de eficacia y seguridad de nipocalimab para adultos con polineuropatía desmielinizante inflamatoria crónica (CIDP)

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Estudio de retiro de fase 2/3, multietapa, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de nipocalimab administrado a adultos con polineuropatía desmielinizante inflamatoria crónica (CIDP)

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

201

Fase

  • Fase 2
  • Fase 3

Acceso ampliado

Temporalmente no disponible fuera del ensayo clínico. Ver registro de acceso ampliado.

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Berlin, Alemania, 13347
        • Activo, no reclutando
        • Judisches Krankenhaus Berlin
      • Bochum, Alemania, 44791
        • Terminado
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, Alemania, 6120
        • Activo, no reclutando
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, Alemania, 30625
        • Activo, no reclutando
        • Medizinische Hochschule Hannover
      • Leipzig, Alemania, 4103
        • Terminado
        • Universitaetsklinikum Leipzig
      • Potsdam, Alemania, 14471
        • Terminado
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Buenos Aires, Argentina, C1199ABB
        • Activo, no reclutando
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1428AQK
        • Reclutamiento
        • Instituto Fleni
      • Buenos Aires, Argentina, C1428
        • Terminado
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, Argentina, 2900
        • Reclutamiento
        • INECO Neurociencias Orono
      • Melbourne, Australia, 3004
        • Terminado
        • The Alfred Hospital
      • Parkwood, Australia, 4215
        • Terminado
        • Gold Coast University Hospital
      • Ottawa, Canadá, K1N 6N5
        • Reclutamiento
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Hradec Králové, Chequia, 500 05
        • Activo, no reclutando
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, Chequia, 708 52
        • Terminado
        • Fakultni Nemocnice Ostrava
      • Pardubice, Chequia, 53203
        • Terminado
        • Pardubicka krajska nemocnice a s
      • Floridablanca, Colombia, 681004
        • Terminado
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, Colombia, 50021
        • Activo, no reclutando
        • Instituto Neurológico de Colombia
      • Seoul, Corea del Sur, 05030
        • Terminado
        • Konkuk University Medical Center
      • Seoul, Corea del Sur, 02447
        • Terminado
        • Kyunghee University Medical Center
      • Seoul, Corea del Sur, 135-710
        • Terminado
        • Samsung Medical Center
      • Alicante, España, 03010
        • Activo, no reclutando
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, España, 8035
        • Terminado
        • Hosp Univ Vall D Hebron
      • Bilbao, España, 48013
        • Activo, no reclutando
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, España, 20014
        • Terminado
        • Hosp. Univ. Donostia
      • Madrid, España, 28040
        • Terminado
        • Hosp. Clinico San Carlos
      • Seville, España, 41009
        • Activo, no reclutando
        • Hosp. Virgen Macarena
    • Colorado
      • Centennial, Colorado, Estados Unidos, 80112
        • Activo, no reclutando
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, Estados Unidos, 33067
        • Terminado
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, Estados Unidos, 32751
        • Terminado
        • Neurology Associates PA
      • Miami, Florida, Estados Unidos, 33136
        • Activo, no reclutando
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Terminado
        • Augusta University
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Terminado
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Terminado
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Terminado
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Terminado
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64128
        • Terminado
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, Estados Unidos, 10032
        • Terminado
        • The Neurological Institute of New York
      • Patchogue, New York, Estados Unidos, 11772
        • Terminado
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Terminado
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Activo, no reclutando
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, Estados Unidos, 78756
        • Terminado
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Activo, no reclutando
        • Advocate Health - Aurora St. Luke's Medical Center
      • Bordeaux, Francia, 33000
        • Terminado
        • CHU Bordeaux
      • Bron, Francia, 69699
        • Terminado
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, Francia, 94270
        • Activo, no reclutando
        • Hopital de Bicetre
      • Marseille, Francia, 13385
        • Activo, no reclutando
        • Hopital de la Timone
      • Nice, Francia, 06000
        • Activo, no reclutando
        • Hopital PASTEUR
      • Nîmes, Francia, 30029
        • Activo, no reclutando
        • CHU Nimes Hopital Caremeau
      • Paris, Francia, 75013
        • Terminado
        • Hopital de la Pitie Salpetriere
      • Paris, Francia, 75019
        • Terminado
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, Francia, 67200
        • Activo, no reclutando
        • CHRU Strasbourg
      • Athens, Grecia, 12462
        • Reclutamiento
        • Attikon General Hospital of Athens
      • Athens, Grecia, 11527
        • Terminado
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, Grecia, 26504
        • Terminado
        • Patras University Hospital
      • Thessaloniki, Grecia, 54636
        • Reclutamiento
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Catania, Italia, 95123
        • Terminado
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, Italia, 16132
        • Terminado
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, Italia, 20144
        • Terminado
        • Casa di Cura del Policlinico
      • Milan, Italia, 20133
        • Terminado
        • Istituto Neurologico Carlo Besta
      • Naples, Italia, 80131
        • Activo, no reclutando
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, Italia, 10043
        • Terminado
        • Aou San Luigi Gonzaga
      • Pavia, Italia, 27100
        • Terminado
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, Italia, 00168
        • Terminado
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, Italia, 20086
        • Terminado
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, Japón, 070-0901
        • Activo, no reclutando
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, Japón, 113 8519
        • Activo, no reclutando
        • Institute of Science Tokyo Hospital
      • Chiba, Japón, 260-8677
        • Terminado
        • Chiba University Hospital
      • Hamamatsu, Japón, 430-8558
        • Activo, no reclutando
        • Seirei Hamamatsu General Hospital
      • Isehara, Japón, 259-1193
        • Activo, no reclutando
        • Tokai University Hospital
      • Kobe, Japón, 650 0047
        • Terminado
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, Japón, 187-8551
        • Activo, no reclutando
        • National Center of Neurology and Psychiatry
      • Koshigaya, Japón, 343-8555
        • Activo, no reclutando
        • Saitama Medical Center
      • Kumamoto, Japón, 860-8556
        • Terminado
        • Kumamoto University Hospital
      • Nagoya, Japón, 466-8560
        • Activo, no reclutando
        • Nagoya University Hospital
      • Nagoya, Japón, 455-8530
        • Activo, no reclutando
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, Japón, 589 8511
        • Terminado
        • Kindai University Hospital
      • Sendai, Japón, 983-8520
        • Activo, no reclutando
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, Japón, 321 0293
        • Terminado
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, Japón, 162-8666
        • Terminado
        • Tokyo Women's Medical University Hospital
      • Tenri, Japón, 632-0015
        • Terminado
        • Tenri Hospital
      • Toon-shi, Japón, 791-0295
        • Terminado
        • Ehime University Hospital
      • Toyama, Japón, 930-0194
        • Terminado
        • Toyama University Hospital
      • Ube, Japón, 755-8505
        • Terminado
        • Yamaguchi University Hospital
      • Monterrey, México, 64710
        • Terminado
        • i Can Oncology Center
      • Tlalnepantla, México, 54055
        • Reclutamiento
        • Clinical Research Institute S.C.
      • Chorzów, Polonia, 41 500
        • Terminado
        • Centrum Medyczne
      • Krakow, Polonia, 30 539
        • Terminado
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, Polonia, 20 093
        • Terminado
        • Prywatny Gabinet Lekarski
      • Poznan, Polonia, 61 731
        • Activo, no reclutando
        • Clinical Research Center sp z o o MEDIC R s k
      • Beijing, Porcelana, 100191
        • Terminado
        • Peking University Third Hospital
      • Beijing, Porcelana, 100034
        • Terminado
        • Peking University First Hospital
      • Beijing, Porcelana, 100053
        • Activo, no reclutando
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, Porcelana, 100070
        • Activo, no reclutando
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, Porcelana, 130021
        • Activo, no reclutando
        • The First Hospital of Jilin University
      • Changsha, Porcelana, 410008
        • Terminado
        • Xiangya Hospital Central South University
      • Changsha, Porcelana, 410008
        • Activo, no reclutando
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, Porcelana, 610072
        • Terminado
        • Sichuan Provincial Peoples Hospital
      • Chifeng, Porcelana, 024000
        • Terminado
        • Chifeng Municipal Hospital
      • Fuzhou, Porcelana, 350001
        • Activo, no reclutando
        • Fujian Medical University Union Hospital
      • Guangzhou, Porcelana, 510080
        • Activo, no reclutando
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, Porcelana, 250012
        • Activo, no reclutando
        • Qilu Hospital of Shandong University
      • Jinan, Porcelana, 250014
        • Terminado
        • Qianfoshan hospital of Shandong Province
      • Nanchang, Porcelana, 330006
        • Activo, no reclutando
        • The First Affiliated Hospital of NanChang University
      • Shanghai, Porcelana, 200336
        • Terminado
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, Porcelana, 200040
        • Activo, no reclutando
        • Huashan Hospital Fudan University
      • Wuhan, Porcelana, 430023
        • Terminado
        • Renmin Hospital of Wuhan University
      • Xi'an, Porcelana, 710032
        • Terminado
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, Porcelana, 710075
        • Activo, no reclutando
        • Xi 'an GaoXin Hospital
      • Almada, Portugal, 2805-267
        • Activo, no reclutando
        • Hospital Garcia de Orta
      • Braga, Portugal, 4710-243
        • Terminado
        • Hospital de Braga
      • Porto, Portugal, 4200 319
        • Activo, no reclutando
        • Centro Hospitalar de Sao Joao Epe
      • Birmingham, Reino Unido, B15 2TH
        • Terminado
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, Reino Unido, EX2 5DW
        • Terminado
        • Royal Devon & Exeter Hospital
      • Glasgow, Reino Unido, G514TF
        • Activo, no reclutando
        • NHS Greater Glasgow and Clyde
      • London, Reino Unido, NW3 2QG
        • Terminado
        • Royal Free Hospital
      • Sheffield, Reino Unido, S10 2 JF
        • Activo, no reclutando
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Kaohsiung City, Taiwán, 88301
        • Terminado
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwán, 100
        • Activo, no reclutando
        • National Taiwan University Hospital
      • Taipei, Taiwán, 111
        • Activo, no reclutando
        • Shin Kong Wu Ho Su Memorial Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

Otros nombres:
  • JNJ-80202135
  • M281
Comparador de placebos: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Stage B: Time to First Occurrence of a Relapse Event
Periodo de tiempo: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Periodo de tiempo: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
Periodo de tiempo: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Periodo de tiempo: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Periodo de tiempo: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Periodo de tiempo: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Periodo de tiempo: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Periodo de tiempo: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Periodo de tiempo: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Periodo de tiempo: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Periodo de tiempo: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Periodo de tiempo: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Periodo de tiempo: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Periodo de tiempo: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Periodo de tiempo: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Periodo de tiempo: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Periodo de tiempo: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Periodo de tiempo: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

23 de septiembre de 2022

Finalización primaria (Estimado)

15 de diciembre de 2026

Finalización del estudio (Estimado)

11 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

7 de abril de 2022

Primero enviado que cumplió con los criterios de control de calidad

7 de abril de 2022

Publicado por primera vez (Actual)

14 de abril de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR109195
  • 80202135CDP3001 (Otro identificador: Janssen Research & Development, LLC)
  • 2021-003234-37 (Número EudraCT)
  • 2023-508425-28-00 (Identificador de registro: EUCT number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir